# Velcade (Bortezomib) Consolidation After Transplant

> **NCT01539083** · PHASE3 · COMPLETED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 256 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT01539083
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-13
- **Primary completion:** 2015-12-30
- **Final completion:** 2018-01-09
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01539083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01539083, "Velcade (Bortezomib) Consolidation After Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01539083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*